Given that the reliance on copper trafficking in metastasis might vary across the different molecular subtypes of breast cancer and subsequently influence the impact of copper depletion as a therapeutic strategy, we sought to evaluate ATOX1 as a predictive factor for TM treatment outcome of breast cancer patients at high risk of recurrence using tumor tissue sections and follow-up data from the phase II clinical trial described above. This evidence concerns the gene ATOX1 and neoplasm.